SOURCE: StockCall

StockCall

February 01, 2011 08:11 ET

Equity Research on Bristol-Myers Squibb Co. and AstraZeneca plc - Pricing and Expiring Patents Threaten Revenues for Drug Manufacturers

JOHANNESBURG, SOUTH AFRICA--(Marketwire - February 1, 2011) -  www.stockcall.com/ offers investors comprehensive research on the drug manufacturers - major industry and has completed analytical research on Bristol-Myers Squibb Co. (NYSE: BMY) and AstraZeneca plc (NYSE: AZN). Register with us today at www.stockcall.com/ to have free access to these researches. 

Major drug manufacturers are currently focused on contending with governmental price pressure and expiring patents. Getting new drugs to market is also becoming increasingly important as tighter Food and Drug Administration regulations are slowing many drugs' arrival to market. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the drug manufacturers -- major industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the drug manufacturers - major industry can have easy and free access to our analyst research and opinions on Bristol-Myers Squibb Co. and AstraZeneca plc; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

Expiring patents are especially important to Bristol Myers Squib which will see their patent on its $6.66 billion cash cow Plavix expire in 2013. Generic competition should significantly lower revenues seen from the drug but the company still has several drugs working their way through the approval process. Bristol-Myers Squibb Co. research report is accessible for free by registering today at www.stockcall.com/BMY010211.pdf

Moving forward, getting new drugs to market is vital for drug manufactures pressured by government pricing and expiring patents. Generic drug competition has also dented revenues for manufacturers like AstraZeneca Plc. AstraZeneca plc research report is available for free by signing up now at www.stockcall.com/AZN010211.pdf

These aforementioned pressures may lead to more mergers and acquisitions as a way to bypass the slower and more demanding approval process. Revenues from emerging markets are helping to offset some of the losses seen in other areas though. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information